Recent Updates
Recently added Catalysts
KRMD Positive Sentiment Score: 70/100

KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference

Wednesday, July 29, 2026 1 min read
Key Takeaway: KORU Medical Systems, Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026. This event highlights the company's commitment to innovation in large volume subcutaneous infusion solutions. Management's presentation is expected to provide insights into the company's strategic direction and growth potential.

Market Sentiment Analysis

POSITIVE FACTORS

  • KORU Medical is participating in a prominent industry conference.
  • The company focuses on innovative and patient-centric solutions.
  • Management's presentation may enhance visibility and investor interest.

Full Press Release Details

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026. KORU Medical's management is scheduled to present at the Canaccord Genuity 46th Annual

Frequently Asked Questions

When will KORU Medical participate in the conference?

KORU Medical will participate in the conference on August 12th, 2026.

What is the focus of KORU Medical Systems?

KORU Medical focuses on developing innovative large volume subcutaneous infusion solutions.

What type of event is the Canaccord Genuity conference?

It is the 46th Annual Growth Conference organized by Canaccord Genuity.

Who will present at the conference for KORU Medical?

The management team of KORU Medical will present at the conference.

Tags: KRMD Viatris Investor Conferences Healthcare KORU Medical Canaccord Genuity growth conference medical technology
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
Low dilution risk